1.20Open1.74Pre Close3 Volume85 Open Interest15.00Strike Price360.00Turnover63.67%IV6.69%PremiumDec 20, 2024Expiry Date0.21Intrinsic Value100Multiplier30DDays to Expiry0.99Extrinsic Value100Contract SizeAmericanOptions Type-0.4871Delta0.1468Gamma12.59Leverage Ratio-0.0170Theta-0.0062Rho-6.13Eff Leverage0.0171Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet